Abstract:Background Non-small cell lung cancer (NSCLC) is a prevalent and aggressive malignancy with limited therapeutic options. Despite advances in treatment, NSCLC remains a major cause of cancer-related death worldwide. Tumor heterogeneity and therapy resistance present challenges in achieving remission. Research is needed to provide molecular insights, identify new targets, and develop personalized therapies to improve outcomes. Methods The protein expression level and prognostic value of DHX38 in NSCLC were explored in public databases and NSCLC tissue microarrays. DHX38 knockdown and overexpression cell lines were established to evaluate the role of DHX38 in NSCLC. In vitro and in vivo functional experiments were conducted to assess proliferation and metastasis. To determine the underlying molecular mechanism of DHX38 in human NSCLC, proteins that interact with DHX38 were isolated by IP and identified by LC–MS. KEGG analysis of DHX38-interacting proteins revealed the molecular pathway of DHX38 in human NSCLC. Abnormal pathway activation was verified by Western blot analysis and immunohistochemical (IHC) staining. A molecule-specific inhibitor was further used to explore potential therapeutic targets for NSCLC. The pathway-related target that interacted with DHX38 was verified by co-immunoprecipitation(co-IP) experiments. In cell lines with stable DHX38 overexpression, the target protein was knocked down to explore its complementary effect on DHX38 overexpression-induced tumor promotion. Results The protein expression of DHX38 was increased in NSCLC, and patients with high DHX38 expression levels had a poor prognosis. In vitro and in vivo experiments showed that DHX38 promoted the proliferation, migration and invasion of human NSCLC cells. DHX38 overexpression caused abnormal activation of the MAPK pathway and promoted epithelial-mesenchymal transition (EMT) in tumours. SCH772984, a novel specific ERK1/2 inhibitor, significantly reduced the increases in cell proliferation, migration and invasion caused by DHX38 overexpression. The co-IP experiments confirmed that DHX38 interacted with the Ras GTPase-activating protein-binding protein G3BP1. DHX38 regulated the expression of G3BP1. Knocking down G3BP1 in cells with stable DHX38 overexpression prevented DHX38-induced tumor cell proliferation, migration and invasion. Silencing G3BP1 reversed the MAPK pathway activation and EMT induced by DHX38 overexpression. Conclusion In NSCLC, DHX38 functions as a tumor promoter. DHX38 modulates G3BP1 expression, leading to the activation of the MAPK signaling pathway, thus promoting tumor cell proliferation, metastasis, and the progression of epithelial-mesenchymal transition (EMT) in non-small cell lung cancer.

BP 1 contributes to tumor metastasis via upregulation of Slug expression in hepatocellular carcinoma

G3BP1 Contributes to Tumor Metastasis Via Upregulation of Slug Expression in Hepatocellular Carcinoma.

Author Correction: Integrin Β4 Promotes Cell Invasion and Epithelial-Mesenchymal Transition Through the Modulation of Slug Expression in Hepatocellular Carcinoma

G3BP1 Regulates Breast Cancer Cell Proliferation and Metastasis by Modulating PKCζ

G3BP1 promotes human breast cancer cell proliferation through coordinating with GSK-3β and stabilizing β-catenin

The Role of XBP1s in the Metastasis and Prognosis of Hepatocellular Carcinoma

The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma

Loss of G3BP1 suppresses proliferation, migration, and invasion of esophageal cancer cells via Wnt/β‐catenin and PI3K/AKT signaling pathways

G3BP2 regulated by the lncRNA LINC01554 facilitates esophageal squamous cell carcinoma metastasis through stabilizing HDGF transcript

G3BP1 Promotes Tumor Progression and Metastasis Through IL-6/G3BP1/STAT3 Signaling Axis in Renal Cell Carcinomas

Overexpression of Ras-GTPase-activating Protein SH3 Domain-Binding Protein 1 Correlates with Poor Prognosis in Gastric Cancer Patients.

B-Cell Receptor-Associated Protein 31 Promotes Metastasis Via AKT/β-Catenin/Snail Pathway in Hepatocellular Carcinoma

Slug Overexpression Induces Stemness and Promotes Hepatocellular Carcinoma Cell Invasion and Metastasis

Overexpression of G3BP1 facilitates the progression of colon cancer by activating β‐catenin signaling

High expression B3GAT3 is related with poor prognosis of liver cancer

PTBP3 Contributes to the Metastasis of Gastric Cancer by Mediating CAV1 Alternative Splicing

Long noncoding RNA GPC3-AS1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.

GINS1 promotes ZEB1‐mediated epithelial‐mesenchymal transition and tumor metastasis via β‐catenin signaling in hepatocellular carcinoma

Slug promotes hepatocellular cancer cell progression by increasing sox2 and nanog expression.

DHX38 enhances proliferation, metastasis, and EMT progression in NSCLC through the G3BP1-mediated MAPK pathway

GNB1 Promotes Hepatocellular Carcinoma Progression by Targeting BAG2 to Activate P38/MAPK Signaling.